JP2014515036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515036A5 JP2014515036A5 JP2014510798A JP2014510798A JP2014515036A5 JP 2014515036 A5 JP2014515036 A5 JP 2014515036A5 JP 2014510798 A JP2014510798 A JP 2014510798A JP 2014510798 A JP2014510798 A JP 2014510798A JP 2014515036 A5 JP2014515036 A5 JP 2014515036A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- maytansinoid immunoconjugate
- maytansinoid
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11290232.5 | 2011-05-17 | ||
| EP11290232A EP2524929A1 (en) | 2011-05-17 | 2011-05-17 | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| PCT/EP2012/059141 WO2012156455A1 (en) | 2011-05-17 | 2012-05-16 | Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226407A Division JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515036A JP2014515036A (ja) | 2014-06-26 |
| JP2014515036A5 true JP2014515036A5 (https=) | 2014-08-07 |
| JP6050328B2 JP6050328B2 (ja) | 2016-12-21 |
Family
ID=46085972
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510798A Expired - Fee Related JP6050328B2 (ja) | 2011-05-17 | 2012-05-16 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2016226407A Expired - Fee Related JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2017138852A Pending JP2018021020A (ja) | 2011-05-17 | 2017-07-18 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2019087962A Pending JP2019142961A (ja) | 2011-05-17 | 2019-05-08 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226407A Expired - Fee Related JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2017138852A Pending JP2018021020A (ja) | 2011-05-17 | 2017-07-18 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2019087962A Pending JP2019142961A (ja) | 2011-05-17 | 2019-05-08 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US9555126B2 (https=) |
| EP (2) | EP2524929A1 (https=) |
| JP (4) | JP6050328B2 (https=) |
| KR (1) | KR20140043388A (https=) |
| CN (2) | CN107007840A (https=) |
| AR (1) | AR086412A1 (https=) |
| AU (3) | AU2012258254B2 (https=) |
| BR (1) | BR112013029330A8 (https=) |
| CA (1) | CA2835738A1 (https=) |
| CL (1) | CL2013003272A1 (https=) |
| CO (1) | CO6821893A2 (https=) |
| CR (1) | CR20130593A (https=) |
| DO (1) | DOP2013000260A (https=) |
| EA (1) | EA028574B1 (https=) |
| EC (1) | ECSP13013084A (https=) |
| GT (1) | GT201300276A (https=) |
| IL (3) | IL229380B (https=) |
| MA (1) | MA35180B1 (https=) |
| MX (1) | MX347019B (https=) |
| MY (1) | MY163736A (https=) |
| NI (1) | NI201300119A (https=) |
| PE (1) | PE20141018A1 (https=) |
| PH (2) | PH12013502305A1 (https=) |
| SG (2) | SG194894A1 (https=) |
| TN (1) | TN2013000468A1 (https=) |
| TW (3) | TW201834687A (https=) |
| UA (1) | UA114401C2 (https=) |
| UY (1) | UY34077A (https=) |
| WO (1) | WO2012156455A1 (https=) |
| ZA (1) | ZA201309400B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| AU2014312086B2 (en) | 2013-08-30 | 2020-03-12 | Immunogen, Inc. | Antibodies and assays for detection of folate receptor 1 |
| CN105837689B (zh) * | 2015-01-13 | 2020-06-19 | 博生吉安科细胞技术有限公司 | 抗cd19单克隆抗体及其制备方法 |
| WO2016180941A1 (en) * | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
| LT3302550T (lt) | 2015-05-26 | 2019-11-11 | Morphosys Ag | Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas |
| SMT202100541T1 (it) | 2015-08-21 | 2021-11-12 | Morphosys Ag | Combinazioni e loro usi |
| AU2016323968B2 (en) | 2015-09-17 | 2023-07-06 | Immunogen, Inc. | Therapeutic combinations comprising anti-FOLR1 immunoconjugates |
| PT3380525T (pt) | 2015-11-25 | 2024-02-05 | Immunogen Inc | Formulações farmacêuticas e métodos que as utilizam |
| RS62155B1 (sr) | 2016-05-30 | 2021-08-31 | Morphosys Ag | Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata |
| SI3475303T1 (sl) | 2016-06-27 | 2021-12-31 | Morphosys Ag | Formulacija protitelesa proti CD19 |
| IL301786B2 (en) | 2016-10-28 | 2025-09-01 | Morphosys Ag | Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses |
| WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| CN110869765A (zh) * | 2017-04-20 | 2020-03-06 | Adc治疗有限公司 | 组合疗法 |
| MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
| TWI878186B (zh) * | 2017-09-21 | 2025-03-21 | 中國大陸商上海藥明生物技術有限公司 | 新型抗cd19抗體 |
| AU2018337142B2 (en) | 2017-09-22 | 2025-07-03 | Wuxi Biologics Ireland Limited. | Novel bispecific CD3/CD19 polypeptide complexes |
| MA51629A (fr) | 2018-01-12 | 2020-11-18 | Immunogen Inc | Procédés de production, purification et formulation de conjugués anticorps-médicaments |
| JP7561141B2 (ja) | 2019-04-26 | 2024-10-03 | イミュノジェン・インコーポレーテッド | カンプトテシン誘導体 |
| MX2021013101A (es) | 2019-05-03 | 2022-01-04 | Morphosys Ag | Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. |
| TWI865644B (zh) | 2019-10-31 | 2024-12-11 | 德商莫菲西斯公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| KR20220091576A (ko) * | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | 혈액암의 항-cd47 및 항-cd20 기반 치료 |
| US20210130461A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| CN111303287B (zh) * | 2019-12-05 | 2022-05-20 | 常州费洛斯药业科技有限公司 | 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用 |
| US20230014026A1 (en) | 2020-06-22 | 2023-01-19 | Morphosys Ag | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint |
| EP4225794A1 (en) | 2020-10-06 | 2023-08-16 | Xencor, Inc. | Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle) |
| US20220184208A1 (en) | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| IL318787A (en) | 2022-08-17 | 2025-04-01 | Incyte Corp | Treatment including ANTI-CD19 antibodies and EZH2 modulators |
| WO2025087382A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海先博生物科技有限公司 | 靶向cd19的嵌合抗原受体的治疗用途 |
| WO2025157132A1 (en) | 2024-01-23 | 2025-07-31 | Wuxi Biologics (Shanghai) Co., Ltd. | Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| PL3524611T3 (pl) | 2003-05-20 | 2021-06-14 | Immunogen, Inc. | Udoskonalone czynniki cytotoksyczne zawierające nowe maitansynoidy |
| KR101456728B1 (ko) * | 2006-09-08 | 2014-10-31 | 메디뮨 엘엘씨 | 인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도 |
| CN102365021B (zh) * | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| NZ613647A (en) * | 2009-05-06 | 2015-02-27 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| WO2011050180A1 (en) * | 2009-10-21 | 2011-04-28 | Immunogen, Inc. | Novel dosing regimen and method of treatment |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
-
2011
- 2011-05-17 EP EP11290232A patent/EP2524929A1/en not_active Ceased
-
2012
- 2012-05-16 PE PE2013002503A patent/PE20141018A1/es not_active Application Discontinuation
- 2012-05-16 JP JP2014510798A patent/JP6050328B2/ja not_active Expired - Fee Related
- 2012-05-16 US US14/117,806 patent/US9555126B2/en not_active Expired - Fee Related
- 2012-05-16 SG SG2013083407A patent/SG194894A1/en unknown
- 2012-05-16 EA EA201391714A patent/EA028574B1/ru not_active IP Right Cessation
- 2012-05-16 KR KR1020137033076A patent/KR20140043388A/ko not_active Abandoned
- 2012-05-16 EP EP12721529.1A patent/EP2710034A1/en not_active Withdrawn
- 2012-05-16 WO PCT/EP2012/059141 patent/WO2012156455A1/en not_active Ceased
- 2012-05-16 AU AU2012258254A patent/AU2012258254B2/en not_active Ceased
- 2012-05-16 PH PH1/2013/502305A patent/PH12013502305A1/en unknown
- 2012-05-16 CN CN201611022631.9A patent/CN107007840A/zh active Pending
- 2012-05-16 UA UAA201314732A patent/UA114401C2/uk unknown
- 2012-05-16 BR BR112013029330A patent/BR112013029330A8/pt not_active IP Right Cessation
- 2012-05-16 SG SG10201609729VA patent/SG10201609729VA/en unknown
- 2012-05-16 MX MX2013013455A patent/MX347019B/es active IP Right Grant
- 2012-05-16 MY MYPI2013004057A patent/MY163736A/en unknown
- 2012-05-16 CA CA2835738A patent/CA2835738A1/en not_active Abandoned
- 2012-05-16 CN CN201280023918.7A patent/CN103547596A/zh active Pending
- 2012-05-16 AR ARP120101724A patent/AR086412A1/es unknown
- 2012-05-17 TW TW107102069A patent/TW201834687A/zh unknown
- 2012-05-17 TW TW101117628A patent/TWI601537B/zh not_active IP Right Cessation
- 2012-05-17 UY UY0001034077A patent/UY34077A/es not_active Application Discontinuation
- 2012-05-17 TW TW105134320A patent/TW201726167A/zh unknown
-
2013
- 2013-11-11 IL IL229380A patent/IL229380B/en active IP Right Grant
- 2013-11-12 TN TNP2013000468A patent/TN2013000468A1/fr unknown
- 2013-11-12 GT GT201300276A patent/GT201300276A/es unknown
- 2013-11-12 DO DO2013000260A patent/DOP2013000260A/es unknown
- 2013-11-12 NI NI201300119A patent/NI201300119A/es unknown
- 2013-11-13 CR CR20130593A patent/CR20130593A/es unknown
- 2013-11-14 CL CL2013003272A patent/CL2013003272A1/es unknown
- 2013-12-12 MA MA36558A patent/MA35180B1/fr unknown
- 2013-12-12 ZA ZA2013/09400A patent/ZA201309400B/en unknown
- 2013-12-16 EC ECSP13013084 patent/ECSP13013084A/es unknown
- 2013-12-16 CO CO13293559A patent/CO6821893A2/es unknown
-
2016
- 2016-07-21 AU AU2016206317A patent/AU2016206317A1/en not_active Abandoned
- 2016-11-22 JP JP2016226407A patent/JP6181273B2/ja not_active Expired - Fee Related
- 2016-12-16 US US15/381,266 patent/US20170196988A1/en not_active Abandoned
-
2017
- 2017-07-18 JP JP2017138852A patent/JP2018021020A/ja active Pending
- 2017-07-28 PH PH12017501368A patent/PH12017501368A1/en unknown
-
2018
- 2018-02-12 IL IL257475A patent/IL257475A/en unknown
- 2018-03-01 AU AU2018201504A patent/AU2018201504A1/en not_active Abandoned
- 2018-12-16 IL IL263728A patent/IL263728A/en unknown
-
2019
- 2019-05-08 JP JP2019087962A patent/JP2019142961A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515036A5 (https=) | ||
| JP6181273B2 (ja) | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| Cang et al. | Novel CD20 monoclonal antibodies for lymphoma therapy | |
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| JP2016531915A5 (https=) | ||
| JP2018500014A5 (https=) | ||
| JP2016538318A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| JP2020536112A (ja) | Ｔ細胞免疫療法のための組合せ及びその使用 | |
| JP2015500822A5 (https=) | ||
| JP2021501776A5 (https=) | ||
| WO2017066583A1 (en) | A nanomaterial complex comprising graphene oxide associated with a therapeutic agent and methods of use | |
| JP2020510039A5 (https=) | ||
| EP2849784A1 (en) | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) | |
| JP2015517512A (ja) | Ｃｄ３７抗体の更なる薬剤との併用 | |
| JP2016525560A5 (https=) | ||
| JP2024028865A (ja) | 抗ｃｄ１９抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム | |
| US20230014026A1 (en) | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint | |
| JP2015516980A (ja) | Ｃｄ３７抗体とベンダムスチンとの併用 | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| Doubek et al. | Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? | |
| Stathis et al. | New agents for the treatment of lymphoma | |
| US20160106837A1 (en) | Combination of cd37 antibodies with chlorambucil | |
| TW202408575A (zh) | 奧布替尼與ｔａｆａｓｉｔａｍａｂ聯合用藥治療 |